Double-blind cross-over study of levamisole as immunoprophylaxis for recurrent herpes progenitalis.
A double-blind cross-over study of the immunoprophylactic influence of levamisole was undertaken in a study of forty patients with chronic, recurrent herpes progenitalis. Clinical records failed to show significant reduction in the frequency or severity of attacks in levamisole-treated patients when compared with placebo-treated control patients. At evaluation six months after levamisole administration, there was no essential alteration in the course of the disease in the initial treatment group.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005831:Genital Diseases, Female / Q000276:immunology / Q000517:prevention & control*; D005832:Genital Diseases, Male / Q000276:immunology / Q000517:prevention & control*; D006561:Herpes Simplex / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence
D007978:Levamisole